MedTrace Logo

Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines

NCT05067946 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2022-04-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy, safety and immunogenicity of GX-19N in healthy individuals who have received one of COVID-19 vaccine authorized for emergency use.

Conditions

  • SARS-CoV2 Infection

Interventions

BIOLOGICAL

GX-19N

DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen

OTHER

Placebo

GX-19N formulation buffer

Sponsors & Collaborators

  • PT Kalbe Farma Tbk

    collaborator INDUSTRY

  • Genexine, Inc.

    lead INDUSTRY

Principal Investigators

  • JungWon Woo, Ph.D. · Genexine, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-31
Primary Completion
2022-10-31
Completion
2023-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05067946 on ClinicalTrials.gov